Rapid decline of neutralizing antibodies is associated with decay of IgM in adults recovered from mild COVID-19

Dong, 2020, An interactive web-based dashboard to track COVID-19 in real time, Lancet Infect. Dis., 20, 533, 10.1016/S1473-3099(20)30120-1

Fafi-Kremer, 2020, Serologic responses to SARS-CoV-2 infection among hospital staff with mild disease in eastern France, EBioMedicine, 59, 102915, 10.1016/j.ebiom.2020.102915

Guo, 2020, Profiling Early Humoral Response to Diagnose Novel Coronavirus Disease (COVID-19), Clin. Infect. Dis., 71, 778, 10.1093/cid/ciaa310

To, 2020, Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study, Lancet Infect. Dis., 20, 565, 10.1016/S1473-3099(20)30196-1

Zhao, 2019, Antibody responses to SARS-CoV-2 in patients with novel coronavirus disease 2019, Clin. Infect. Dis., 71, 2027, 10.1093/cid/ciaa344

Amanat, 2020, A serological assay to detect SARS-CoV-2 seroconversion in humans, Nat. Med., 26, 1033, 10.1038/s41591-020-0913-5

Duan, 2020, Effectiveness of convalescent plasma therapy in severe COVID-19 patients, Proc. Natl. Acad. Sci. USA, 117, 9490, 10.1073/pnas.2004168117

Long, 2020, Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections, Nat. Med., 26, 1200, 10.1038/s41591-020-0965-6

Piccoli, 2020, Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology, Cell, 183, 1024, 10.1016/j.cell.2020.09.037

Ripperger, 2020, Orthogonal SARS-CoV-2 Serological Assays Enable Surveillance of Low Prevalence Communities and Reveal Durable Humoral Immunity, Immunity, 53, 925, 10.1016/j.immuni.2020.10.004

Wu, 2020, Evaluating the Association of Clinical Characteristics With Neutralizing Antibody Levels in Patients Who Have Recovered From Mild COVID-19 in Shanghai, China, JAMA Intern. Med., 180, 1356, 10.1001/jamainternmed.2020.4616

Brouwer, 2020, Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability, Science, 369, 643, 10.1126/science.abc5902

Hansen, 2020, Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail, Science, 369, 1010, 10.1126/science.abd0827

Kreer, 2020, Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients, Cell, 182, 843, 10.1016/j.cell.2020.06.044

Robbiani, 2020, Convergent antibody responses to SARS-CoV-2 in convalescent individuals, Nature, 584, 437, 10.1038/s41586-020-2456-9

Seydoux, 2020, Analysis of a SARS-CoV-2-Infected Individual Reveals Development of Potent Neutralizing Antibodies with Limited Somatic Mutation, Immunity, 53, 98, 10.1016/j.immuni.2020.06.001

Shi, 2020, A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2, Nature, 584, 120, 10.1038/s41586-020-2381-y

Wu, 2020, A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2, Science, 368, 1274, 10.1126/science.abc2241

Cao, 2007, Disappearance of antibodies to SARS-associated coronavirus after recovery, N. Engl. J. Med., 357, 1162, 10.1056/NEJMc070348

Choe, 2017, MERS-CoV Antibody Responses 1 Year after Symptom Onset, South Korea, 2015, Emerg. Infect. Dis., 23, 1079, 10.3201/eid2307.170310

Anderson, 2020, Lack of cross-neutralization by SARS patient sera towards SARS-CoV-2, Emerg. Microbes Infect., 9, 900, 10.1080/22221751.2020.1761267

Gudbjartsson, 2020, Humoral Immune Response to SARS-CoV-2 in Iceland, N. Engl. J. Med., 383, 1724, 10.1056/NEJMoa2026116

Wajnberg, 2020, Robust neutralizing antibodies to SARS-CoV-2 infection persist for months, Science, 370, 1227, 10.1126/science.abd7728

Prévost, 2020, Cross-Sectional Evaluation of Humoral Responses against SARS-CoV-2 Spike, Cell Rep. Med., 1, 100126, 10.1016/j.xcrm.2020.100126

Gaebler, 2021, Evolution of antibody immunity to SARS-CoV-2, Nature, 591, 639, 10.1038/s41586-021-03207-w

Rodda, 2021, Functional SARS-CoV-2-Specific Immune Memory Persists after Mild COVID-19, Cell, 184, 169, 10.1016/j.cell.2020.11.029

Crawford, 2020, Protocol and Reagents for Pseudotyping Lentiviral Particles with SARS-CoV-2 Spike Protein for Neutralization Assays, Viruses, 12, E513, 10.3390/v12050513

Fisher, 2020, Oral Immunization with HIV-1 Envelope SOSIP trimers elicits systemic immune responses and cross-reactive anti-V1V2 antibodies in non-human primates, PLoS ONE, 15, e0233577, 10.1371/journal.pone.0233577

Chen, 2020, A comprehensive, longitudinal analysis of humoral responses specific to four recombinant antigens of SARS-CoV-2 in severe and non-severe COVID-19 patients, PLoS Pathog., 16, e1008796, 10.1371/journal.ppat.1008796

Garcia-Beltran, 2021, COVID-19 neutralizing antibodies predict disease severity and survival, Cell, 184, 476, 10.1016/j.cell.2020.12.015

Klingler, 2021, Role of IgM and IgA Antibodies in the Neutralization of Severe Acute Respiratory Syndrome Coronavirus 2, J. Infect. Dis., 223, 957, 10.1093/infdis/jiaa784

Sterlin, 2021, IgA dominates the early neutralizing antibody response to SARS-CoV-2, Sci. Transl. Med., 13, eabd2223, 10.1126/scitranslmed.abd2223

Liu, 2020, Disappearance of antibodies to SARS-CoV-2 in a -COVID-19 patient after recovery, Clin. Microbiol. Infect., 26, 1703, 10.1016/j.cmi.2020.07.009

Beaudoin-Bussières, 2020, Decline of Humoral Responses against SARS-CoV-2 Spike in Convalescent Individuals, MBio, 11, e02590-20, 10.1128/mBio.02590-20

Perreault, 2020, Waning of SARS-CoV-2 RBD antibodies in longitudinal convalescent plasma samples within 4 months after symptom onset, Blood, 136, 2588, 10.1182/blood.2020008367

Isho, 2020

Wajnberg, 2020

Wrapp, 2020, Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation, Science, 367, 1260, 10.1126/science.abb2507